Copenhagen, 2013-12-19 10:27 CET (GLOBE NEWSWIRE) -- Company Announcement
No. 28/2013
Zealand Pharma (NASDAQ OMX Copenhagen: ZEAL) announces the following dates for the company’s planned financial reporting in 2014:
20 March Interim report, 4Q 2013 and Annual Report 2013
29 April Interim report, 1Q 2014
21 August Interim report, 1H 2014
7 November Interim report, 9 months 2014
The Annual General Meeting will be held on Tuesday 29 April 2014.
The Financial Calendar for 2014 is also available at www.zealandpharma.dk/investors
***
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark, with a leading position in the invention, design and development of novel peptide therapeutics. The company has built a broad and mature pipeline of drug candidates, all invented in house. The therapeutic focus is on cardio-metabolic diseases, diabetes/obesity in particular, and the lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes. Lixisenatide (licensed globally to and marketed by Sanofi as Lyxumia®) is approved in several countries, including Europe and Japan. The product is still undergoing regulatory review in certain countries, and in the U.S., an NDA is planned submitted in 2015, after completion of the ELIXA CV outcome study.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com
@ZealandPharma
